Indacaterol | Salmeterol | Placebo | |
Subjects n | 330 | 333 | 335 |
Patients with any adverse event(s) | 169 (51.2) | 152 (45.6) | 156 (46.6) |
COPD worsening | 60 (18.2) | 51 (15.3) | 65 (19.4) |
Nasopharyngitis | 24 (7.3) | 29 (8.7) | 21 (6.3) |
Upper respiratory tract infection | |||
Bacterial | 14 (4.2) | 3 (0.9) | 5 (1.5) |
Viral | 10 (3.0) | 3 (0.9) | 7 (2.1) |
Lower respiratory tract infection | 9 (2.7) | 13 (3.9) | 8 (2.4) |
Back pain | 7 (2.1) | 12 (3.6) | 6 (1.8) |
Data are presented as n (%) unless otherwise stated. Most common events listed for ≥3% of patients in either indacaterol or salmeterol groups. COPD: chronic obstructive pulmonary disease.